marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 10-31-2024
BioMarin Pharmaceutical Balance Sheet 2011-2024 | BMRN
Annual Balance Sheet BioMarin Pharmaceutical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-746 M | -716 M | -577 M | 435 M | 411 M | 927 M | 576 M | 275 M | 461 M | -148 M | 303 M | 168 M | 451 M |
Long Term Debt |
77 K | 184 K | 1.96 M | 1.08 B | 486 M | 830 M | 814 M | 661 M | 662 M | 658 M | 656 M | 325 M | 348 M |
Long Term Debt Current |
8.64 M | 8.09 M | 8.2 M | 8.89 M | 7.45 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 635 M | 936 M | 1.01 B | 818 M | 883 M | 727 M | 725 M | 415 M | 437 M |
Total Current Liabilities |
1.18 B | 589 M | 546 M | 493 M | 933 M | 523 M | 817 M | 439 M | 445 M | 236 M | 183 M | 170 M | 94.1 M |
Total Liabilities |
1.89 B | 1.77 B | 1.74 B | 1.74 B | 1.57 B | 1.46 B | 1.82 B | 1.26 B | 1.33 B | 963 M | 908 M | 586 M | 531 M |
Deferred Revenue |
4.62 M | 711 K | 6.96 M | 152 K | 13 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-622 M | -789 M | -931 M | -862 M | -1.72 B | -1.69 B | -1.64 B | -1.52 B | -1.02 B | -850 M | -716 M | -539 M | -425 M |
Total Assets |
6.84 B | 6.38 B | 6 B | 5.85 B | 4.69 B | 4.43 B | 4.63 B | 4.02 B | 3.73 B | 2.49 B | 2.25 B | 1.6 B | 1.3 B |
Cash and Cash Equivalents |
755 M | 725 M | 587 M | 649 M | 437 M | 494 M | 598 M | 408 M | 397 M | 875 M | 569 M | 181 M | 46.3 M |
Book Value |
4.95 B | 4.6 B | 4.27 B | 4.11 B | 3.12 B | 2.97 B | 2.81 B | 2.77 B | 2.4 B | 1.53 B | 1.34 B | 1.02 B | 773 M |
Total Shareholders Equity |
4.95 B | 4.6 B | 4.27 B | 4.1 B | 3.12 B | 2.97 B | 2.81 B | 2.77 B | 2.4 B | 1.53 B | 1.34 B | 1.02 B | 773 M |
All numbers in USD currency
Quarterly Balance Sheet BioMarin Pharmaceutical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
595 M | 594 M | 594 M | 593 M | 593 M | 1.08 B | 1.08 B | 1.08 B | 1.08 B | - | 1.08 B | 1.08 B | 1.08 B | 1.08 B | 1.08 B | 4.01 M | 4.57 M | 4.96 M | 5.84 M | 6.71 M | 6.71 M | 6.71 M | 6.71 M | 830 M | 830 M | 830 M | 830 M | 814 M | 814 M | 814 M | 814 M | 661 M | 661 M | 661 M | 661 M | 662 M | 662 M | 662 M | 662 M | 643 M | 658 M | 658 M | 658 M | 656 M | 656 M | 656 M | 656 M | 325 M | 325 M | 325 M | 325 M | 348 M | 348 M | 348 M | 348 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.44 B | 1.78 B | 1.8 B | 1.89 B | 1.86 B | 1.78 B | 1.77 B | 1.77 B | 1.7 B | - | 1.67 B | 1.74 B | 1.71 B | 1.66 B | 1.64 B | 1.74 B | 1.74 B | 1.74 B | 1.74 B | 1.57 B | 1.57 B | 1.57 B | 1.57 B | 1.46 B | 1.46 B | 1.46 B | 1.46 B | 1.82 B | 1.82 B | 1.82 B | 1.82 B | 1.26 B | 1.26 B | 1.26 B | 1.26 B | 1.33 B | 1.33 B | 1.33 B | 1.33 B | 947 M | 963 M | 963 M | 963 M | 903 M | 903 M | 903 M | 903 M | 553 M | 586 M | 586 M | 586 M | 533 M | 531 M | 531 M | 531 M |
Deferred Revenue |
2.35 M | 1.91 M | 5.15 M | 4.62 M | - | - | - | - | 415 K | - | 306 K | 6.96 M | 9.66 M | 11 M | 11.2 M | 152 K | 11.8 M | 11.8 M | 11.8 M | 13 M | 10.7 M | 13 M | 13 M | 1.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-320 M | -426 M | -533 M | -622 M | -642 M | -682 M | -738 M | -789 M | -789 M | - | -805 M | -931 M | -868 M | -831 M | -844 M | -862 M | -862 M | -862 M | -862 M | -1.72 B | -1.72 B | -1.72 B | -1.72 B | -1.69 B | -1.69 B | -1.69 B | -1.69 B | -1.64 B | -1.64 B | -1.64 B | -1.64 B | -1.52 B | -1.52 B | -1.52 B | -1.52 B | -1.02 B | -1.02 B | -1.02 B | -1.02 B | -850 M | -850 M | -850 M | -850 M | -716 M | -716 M | -716 M | -716 M | -539 M | -539 M | -539 M | -539 M | -425 M | -425 M | -425 M | -425 M |
Total Assets |
6.85 B | 7.07 B | 6.87 B | 6.84 B | 6.76 B | 6.56 B | 6.43 B | 6.38 B | 6.26 B | - | 6.06 B | 6 B | 5.98 B | 5.9 B | 5.81 B | 5.85 B | 5.85 B | 5.85 B | 5.85 B | 4.69 B | 4.69 B | 4.69 B | 4.69 B | 4.43 B | 4.43 B | 4.43 B | 4.43 B | 4.63 B | 4.63 B | 4.63 B | 4.63 B | 4.02 B | 4.02 B | 4.02 B | 4.02 B | 3.73 B | 3.73 B | 3.73 B | 3.73 B | 2.48 B | 2.49 B | 2.49 B | 2.49 B | 2.24 B | 2.24 B | 2.24 B | 2.24 B | 1.57 B | 1.6 B | 1.6 B | 1.6 B | 1.31 B | 1.3 B | 1.3 B | 1.3 B |
Cash and Cash Equivalents |
675 M | 972 M | 747 M | 755 M | 785 M | 694 M | 580 M | 725 M | 762 M | 620 M | 605 M | 587 M | 617 M | 642 M | 667 M | 649 M | 649 M | 649 M | 649 M | 437 M | 437 M | 437 M | 437 M | 494 M | 494 M | 494 M | 494 M | 598 M | 598 M | 598 M | 598 M | 408 M | 408 M | 408 M | 408 M | 397 M | 397 M | 397 M | 397 M | 875 M | 875 M | 875 M | 875 M | 569 M | 569 M | 569 M | 569 M | 181 M | 181 M | 181 M | 181 M | 46.3 M | 46.3 M | 46.3 M | 46.3 M |
Book Value |
5.41 B | 5.29 B | 5.07 B | 4.95 B | 4.9 B | 4.78 B | 4.66 B | 4.6 B | 4.57 B | - | 4.39 B | 4.27 B | 4.27 B | 4.24 B | 4.16 B | 4.11 B | 4.11 B | 4.11 B | 4.11 B | 3.12 B | 3.12 B | 3.12 B | 3.12 B | 2.97 B | 2.97 B | 2.97 B | 2.97 B | 2.81 B | 2.81 B | 2.81 B | 2.81 B | 2.77 B | 2.77 B | 2.77 B | 2.77 B | 2.4 B | 2.4 B | 2.4 B | 2.4 B | 1.53 B | 1.53 B | 1.53 B | 1.53 B | 1.34 B | 1.34 B | 1.34 B | 1.34 B | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 773 M | 773 M | 773 M | 773 M |
Total Shareholders Equity |
5.41 B | 5.29 B | 5.07 B | 4.95 B | 4.9 B | 4.78 B | 4.66 B | 4.6 B | 4.57 B | 4.5 B | 4.39 B | 4.27 B | 4.26 B | 4.24 B | 4.16 B | 4.11 B | 4.11 B | 4.11 B | 4.11 B | 3.12 B | 3.12 B | 3.12 B | 3.12 B | 2.97 B | 2.97 B | 2.97 B | 2.97 B | 2.81 B | 2.81 B | 2.81 B | 2.81 B | 2.77 B | 2.77 B | 2.77 B | 2.77 B | 2.4 B | 2.4 B | 2.4 B | 2.4 B | 1.53 B | 1.53 B | 1.53 B | 1.53 B | 1.34 B | 1.34 B | 1.34 B | 1.34 B | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 773 M | 773 M | 773 M | 773 M |
All numbers in USD currency